Argent BioPharma Ltd (ASX:RGT) has received a notice of initial substantial holding from Oak Capital Partners LLC, disclosing a relevant interest of 16,741,441 fully paid ordinary shares, representing 14.20% voting power in the company, with the substantial holder date recorded as 11 July 2023.

Key Points

  • Oak Capital Partners LLC holds 16,741,441 fully paid ordinary shares in Argent BioPharma Ltd, equating to 14.20% voting power.
  • The substantial holder date is recorded as 11 July 2023, with the Form 603 noting a delay in filing, with sections 2 to 5 reflecting shares held on the date of the form.
  • Shares were acquired across four transactions: 7 November 2023 (5,870,718 shares for US$1,500,000), 17 July 2024 (2,500,000 shares for US$2,000,000), 23 April 2025 (2,500,000 shares via equity true-up), and 11 November 2026 (5,870,723 shares for US$1,500,000).
  • Oak Capital Partners LLC is both the holder of relevant interest and the registered holder of all 16,741,441 ordinary shares, with no associates disclosed.

Initial Substantial Holder Notice Details

According to the Form 603 filing lodged with the ASX, Oak Capital Partners LLC became a substantial holder in Argent BioPharma Ltd (ACN 116 800 269) as of 11 July 2023. The filing states that due to a delay in lodgement, sections 2 to 5 of the form reflect the number of fully paid ordinary shares held on the date the form was completed. The nature of Oak Capital Partners LLC's relevant interest is recorded as holder of the securities, with no associates identified. The form was signed by Yitzchok Rokowsky in his capacity as Managing Director, dated 11 November 2026.

Share Acquisition Transactions Disclosed

The filing sets out four separate acquisitions of ordinary shares by Oak Capital Partners LLC within the consideration section of the Form 603. On 7 November 2023, Oak Capital Partners LLC acquired 5,870,718 ordinary shares for cash consideration of US$1,500,000. On 17 July 2024, a further 2,500,000 ordinary shares were acquired for US$2,000,000. On 23 April 2025, an additional 2,500,000 ordinary shares were acquired via an equity true-up arrangement. On 11 November 2026, Oak Capital Partners LLC acquired 5,870,723 ordinary shares for US$1,500,000.

Voting Power and Registered Holder Position

The filing discloses that the total number of votes attached to Oak Capital Partners LLC's relevant interest in Argent BioPharma Ltd is 16,741,441, corresponding to a voting power of 14.20%. Oak Capital Partners LLC is listed as both the holder of the relevant interest and the registered holder of the securities, with no third party identified as a person entitled to be registered as holder. The address of Oak Capital Partners LLC is recorded in the filing as 1608 Route 88, Suite 200, Brick, New Jersey 08724.